Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyBlue Cross Blue Shield KS Filsuvez Coverage Update…
    Ask Trek AI about this page
    Currentblue cross blue shield - kansasPolicy N/A

    Filsuvez Medical Drug Criteria

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical policy outlining prior authorization criteria, coding, and coverage rules for Filsuvez topical gel for treatment of partial-thickness wounds in patients with inherited epidermolysis bullosa for Blue Cross Blue Shield of Kansas members.

    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyFilsuvez Medical Drug Criteria
    Policy CodePolicy N/A
    Change TypeMaterial clinical and operational revisions
    Effective DateAug 1, 2024
    Last ReviewJan 27, 2026
    Next Review DateJan 27, 2026
    Key ActionObtain prior authorization and submit medical records documenting genetic testing confirmation of dystrophic or junctional EB when required.
    SourceLink
    POLICY UPDATE CHANGES

    Removed additional testing requirements of IFM or TEM and updated diagnosis and genetic testing requirements.

    Added disallowance requirement for combination therapy on the same wound of gene therapy product.

    Moved/indented FDA age requirements to bypass continuation of therapy and standardized formatting.

    Added HCPCS code J3490 to coding section.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4 monthsInitial approval length
    12 monthsRenewal approval length
    J3490Billing code added
    n=223Pivotal trial size
    41.3% vs 28.9%Wound closure 45d

    Coverage Criteria for Filsuvez (birch triterpenes) topical gel

    Initial Therapy

    Covered when ALL of the following are met

    Initial Authorization

    • Agent eligibility

      • Continuation of therapy option: The requested agent is eligible for continuation of therapy AND ONE of: the patient has been treated with the requested agent (starting on samples is not approvable) within the past 90 days OR the prescriber states the patient has been treated with the requested agent (starting on samples is not approvable) within the past 90 days AND is at risk if therapy is changed.
      • New use option: ALL of the following: (1) ONE of: a) diagnosis of dystrophic or junctional epidermolysis bullosa confirmed by genetic testing (medical records required) OR b) another FDA-labeled indication for the requested agent; (2) If the patient has an FDA-approved indication, then ONE of: the patient's age is within FDA labeling for the requested indication OR there is support for using the requested agent for the patient's age for the requested indication; (3) the patient does NOT have current evidence or a history of squamous cell carcinoma on the area to be treated; (4) the patient does NOT have an active infection on the area to be treated.
    • Prescriber requirement: Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, geneticist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • Combination therapy restriction: The patient will NOT be using the requested agent in combination with a gene therapy agent on the area to be treated.
    • Contraindications: The patient does NOT have any FDA labeled contraindications to the requested agent.
    • Authorization duration: Length of Approval: 4 months.

    Renewal / Continued Therapy

    Renewal approved when ALL of the following are met

    Renewal Authorization

    • Agent eligibility

      • Continuation of therapy option: The requested agent is eligible for continuation of therapy AND ONE of: the patient has been treated with the requested agent (starting on samples is not approvable) within the past 90 days OR the prescriber states the patient has been treated with the requested agent (starting on samples is not approvable) within the past 90 days AND is at risk if therapy is changed.
      • New use option: ALL of the following: (1) ONE of: a) diagnosis of dystrophic or junctional epidermolysis bullosa confirmed by genetic testing (medical records required) OR b) another FDA-labeled indication for the requested agent; (2) If the patient has an FDA-approved indication, then ONE of: the patient's age is within FDA labeling for the requested indication OR there is support for using the requested agent for the patient's age for the requested indication; (3) the patient does NOT have current evidence or a history of squamous cell carcinoma on the area to be treated; (4) the patient does NOT have an active infection on the area to be treated.

    Renewal After Initial Approval (Clinical benefit)

    Covered when ALL of the following are met

    Renewal after prior approval

    • Prior approval: The patient has been previously approved for the requested agent through the plan's prior authorization criteria.
    • Clinical benefit: The patient has had clinical benefit with the requested agent.
    • Safety checks: No current evidence or a history of squamous cell carcinoma on the area to be treated AND no active infection on the area to be treated.
    • Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, geneticist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis.

    Use of the requested agent in combination with a gene therapy agent on the same treated area is disallowed. This prohibition applies to both initial and renewal approvals and is an explicit requirement for coverage.

    For continuation of therapy, documentation must show the patient was treated with the requested agent within the past 90 days. Samples are not approvable evidence of prior use and cannot be used to establish prior treatment for continuation requests.

    Requests that do not meet the plan's stated initial or renewal criteria will be considered not medically necessary. Examples of unmet criteria that would render a request not medically necessary include: lack of required diagnostic confirmation (for new use, absence of genetic testing confirming dystrophic or junctional EB when required or no alternate FDA-labeled indication documented); presence or history of squamous cell carcinoma on the area to be treated; an active infection on the area to be treated; or failure to show that the prescriber is a specialist in the patient’s diagnosis or has consulted one.

    Other situations that may make a request not medically necessary include use of samples as the sole evidence of prior treatment for continuation (samples are not approvable) or any plan-requested combination therapy that includes a gene therapy agent applied to the same treated area.

    Coding and Billing

    Included HCPCS CodesHCPCS
    J3490Unclassified drug
    inv-07: Target wound size — key parameter for product use/trial entry
    Target wound size (trial definition)Partial-thickness wound 10-50 cm^2
    Target wound duration (trial entry)Present for 21 days to 9 months prior to screening
    Application instructions (trial)Investigational product applied ~1 mm to all wounds at each dressing change every 1 to 4 days for 90 days

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; approval when clinical criteria met

    Prior authorization is required. Initial approval is granted when all clinical criteria in the policy are met, including diagnosis/continuation options, prescriber specialty/consultation, absence of current or prior squamous cell carcinoma on the treated area, no active infection on the treated area, no FDA-labeled contraindications, and confirmation that the agent will not be used in combination with a gene therapy on the same treated area. Length of initial approval: 4 months.

    • Codes: J3490 (HCPCS) may be used for billing.
    Step Therapy

    No step therapy (fail-first) requirements listed

    No fail-first or other step therapy requirements are specified in this policy; the document states that no specific step therapy (fail-first) requirements are listed.

    Background on Condition and Evidence

    Epidermolysis bullosa (EB) comprises a group of rare inherited disorders characterized by skin fragility and recurrent blistering due to defects in proteins that mediate skin adhesion. Major subtypes include dystrophic and junctional EB, which are specifically referenced in the coverage criteria. Management is primarily supportive and may involve specialists such as dermatologists or geneticists.

    Filsuvez (birch triterpenes topical gel) was evaluated for treatment of partial-thickness wounds in patients with inherited EB. Coverage requirements reference diagnostic confirmation (genetic testing for dystrophic or junctional EB when applicable), specialist involvement, and safety precautions including absence of current or prior squamous cell carcinoma and no active infection on the area to be treated. Initial approvals are limited in duration (4 months) with renewal pathways for patients demonstrating clinical benefit (renewal approvals up to 12 months).

    Definitions and Operational Terms

    inv-13: Partial-thickness wound — Target wound defined in trial as partial-thickness wound 10-50 cm^2 present for 21 days to 9 months prior to screening
    Definition (trial)Partial-thickness wound defined as 10-50 cm^2 in surface area
    Required wound chronicityWound present for 21 days to 9 months prior to screening
    Trial population contextTarget wound was the single wound selected by investigator for primary efficacy endpoint in the EASE trial (N=223)
    inv-14: Continuation of therapy — Prior treatment within past 90 days (samples not approvable) or prescriber statement of prior treatment
    Definition of continuationPatient has been treated with the requested agent within the past 90 days (starting on samples is not approvable)
    Alternative for continuation
    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyFilsuvez Medical Drug Criteria
    Policy CodePolicy N/A
    Change TypeMaterial clinical and operational revisions
    Effective DateAug 1, 2024
    Last ReviewJan 27, 2026
    Next Review DateJan 27, 2026
    Key ActionObtain prior authorization and submit medical records documenting genetic testing confirmation of dystrophic or junctional EB when required.
    SourceLink
    On This Page
    Coverage Criteria for Filsuvez (birch triterpenes) topical gelCoding and BillingProvider Actions, Prior Authorization, and DocumentationBackground on Condition and EvidenceDefinitions and Operational Terms
    Prescriber requirement: Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, geneticist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
  1. Combination therapy restriction: The patient will NOT be using the requested agent in combination with a gene therapy agent on the area to be treated.
  2. Contraindications: The patient does NOT have any FDA labeled contraindications to the requested agent.
  3. Authorization duration: Length of Approval: 4 months (note: later renewal section indicates 12 months when previously approved and clinical benefit demonstrated).
  4. Combination therapy restriction: The patient will NOT be using the requested agent in combination with a gene therapy agent on the area to be treated.
  5. Contraindications: The patient does NOT have any FDA labeled contraindications to the requested agent.
  6. Authorization duration: Length of Approval: 12 months.
  7. Documentation Required

    Required medical record documentation

    Provide medical records as documentation of required diagnostic and clinical information: genetic testing confirming dystrophic or junctional EB when applicable, or documentation of another FDA‑labeled indication; records showing prior use of the agent within the past 90 days for continuation requests (starting on samples is not approvable); documentation of specialist prescriber or consultation; and documentation that the treated area has no current or prior squamous cell carcinoma and no active infection.

    • Genetic testing results confirming dystrophic or junctional EB (medical records required).
    • If continuation: records showing patient treated with the requested agent within past 90 days (samples not approvable) or prescriber statement that patient was treated within past 90 days and is at risk if therapy changed.
    • Documentation that prescriber is a specialist (e.g., dermatologist, geneticist) or has consulted one.
    • Documentation that the treated area has no current evidence or history of squamous cell carcinoma and no active infection.
    Denial Risk

    Denial triggers — missing documentation, safety risks, or disallowed combination therapy

    Requests may be denied if required documentation or safety criteria are not met, including missing genetic confirmation when required, lack of documentation of prior use for continuation requests (or use only of samples), presence or history of squamous cell carcinoma on the area to be treated, active infection on the area to be treated, prescriber not a specialist and no specialist consultation documented, or if the requested agent will be used in combination with a gene therapy on the same treated area.

    Prescriber states patient was treated with the requested agent within the past 90 days (starting on samples is not approvable) AND patient is at risk if therapy is changed
    Samples policyUse of samples alone to establish continuation of therapy is not approvable